Pharmacology  ·  Antifungal Agents

Extended-Spectrum Azoles — Voriconazole, Posaconazole & Isavuconazole

Mold coverage, nonlinear kinetics, TDM, visual toxicity, and clinical positioning

Abbreviations: TDM = therapeutic drug monitoring  ·  CYP2C19 = cytochrome P450 2C19  ·  CYP3A4 = cytochrome P450 3A4  ·  QTc = corrected QT interval  ·  IA = invasive aspergillosis  ·  GVHD = graft-versus-host disease  ·  PPI = proton pump inhibitor  ·  DR = delayed-release  ·  CrCl = creatinine clearance  ·  IV = intravenous  ·  SBECD = sulfobutylether-β-cyclodextrin

Extended-Spectrum Azole Comparison
Feature Voriconazole Posaconazole Isavuconazole
Spectrum Aspergillus, Candida (incl. fluconazole-resistant), Fusarium, Scedosporium; no reliable Mucorales Aspergillus, Candida, Mucorales (modest), endemic fungi; broadest spectrum in class Aspergillus, Candida; some Mucorales; no Fusarium or Scedosporium
Oral Bioavailability ~96% fasting; food (especially high-fat) reduces absorption 22%; take 1 hr before or 2 hr after meals Suspension: highly variable, requires high-fat meal; DR tablet: ~54% better and more predictable — preferred formulation ~98% (given as prodrug isavuconazonium); food does not affect absorption; highly reliable
PK Profile Nonlinear (saturable CYP2C19 metabolism) — small dose changes → large level changes; high inter-individual variability; CYP2C19 poor metabolizers reach 4× higher levels Linear kinetics; predictable accumulation; steady-state reached in 7–10 days Linear kinetics; long half-life ~130 hr; once-daily dosing; predictable levels
TDM Mandatory — target trough 1–5.5 mcg/mL; toxicity above 5.5 mcg/mL; levels unpredictable without monitoring Recommended — target trough >0.7 mcg/mL (prophylaxis), >1.0 mcg/mL (treatment) Less critical — linear kinetics; less variability; check if toxicity or efficacy concern
Renal Restriction IV formulation contains SBECD (cyclodextrin vehicle) — accumulates when CrCl <50 mL/min; use oral formulation in renal impairment No renal restriction for any formulation No renal restriction; IV formulation does not contain SBECD
QTc Effect Prolongs QTc — avoid if QTc >500 ms or with other QTc-prolonging drugs Prolongs QTc — same restriction; monitor ECG Shortens QTc — preferred azole in patients with baseline QTc prolongation
Hepatotoxicity Elevated LFTs common; monitor LFTs periodically; discontinue if >5× ULN Elevated LFTs; monitor Elevated LFTs; monitor — similar to voriconazole
Key Indication First-line invasive aspergillosis; Fusarium and Scedosporium infections Prophylaxis in high-risk neutropenic and GVHD patients (IDSA-recommended); salvage Mucorales Primary invasive aspergillosis (non-inferior to voriconazole in SECURE trial); QTc-prolongation risk patients
Voriconazole-Specific Toxicities
Visual Disturbances
Transient Photopsia
  • Affect ~30% of patients within 30–60 minutes of dose
  • Photopsia (flashing lights), altered color perception, blurred vision, photophobia
  • Dose-dependent and fully reversible — resolve spontaneously within 30 minutes
  • Not a reason to stop therapy unless severe or persistent
  • Counsel patients before starting — unexpected visual changes cause unnecessary alarm
Neurotoxicity
Encephalopathy and Hallucinations
  • Encephalopathy, hallucinations, confusion — especially at supratherapeutic levels (>5.5 mcg/mL)
  • Obtain trough level immediately in any patient on voriconazole who develops new CNS symptoms
  • Dose reduction usually resolves symptoms
  • Periostitis (bone pain, periosteal thickening) — seen with prolonged use; fluoride accumulation from SBECD vehicle
Photosensitivity and Skin Cancer
Long-Term Risk
  • Photosensitivity rash — common with prolonged use
  • Squamous cell carcinoma risk with prolonged use in immunocompromised patients — mechanism involves voriconazole-induced photosensitization and UV damage
  • Strict sun protection mandatory for all patients on prolonged voriconazole therapy
  • Annual dermatology surveillance recommended for patients on long-term therapy
Azole Resistance in Aspergillus fumigatus
Environmental Resistance Pathway
CYP51A Mutations from Agricultural Azole Use
  • CYP51A mutations (TR34/L98H, TR46/Y121F/T289A) — alter lanosterol demethylase so azoles cannot bind
  • Arise from selection pressure of agricultural azole fungicides on environmental A. fumigatus populations
  • Globally distributed; rates in some European centers exceed 10–15% of clinical isolates
  • Pan-azole resistance (resistant to voriconazole, posaconazole, and isavuconazole simultaneously) increasingly detected
  • Susceptibility testing before starting empiric voriconazole is now recommended — a susceptible MIC cannot be assumed
Management of Azole-Resistant Aspergillosis
Alternative Strategies
  • Liposomal amphotericin B — not affected by azole resistance mechanisms; preferred alternative
  • Echinocandins — activity against Aspergillus (but not as monotherapy for primary invasive aspergillosis)
  • Combination: voriconazole + anidulafungin showed trend toward improved survival in one RCT vs. voriconazole alone for primary IA
  • No reliable clinical therapy for pan-azole-resistant Aspergillus beyond liposomal amphotericin B or combination regimens — outcomes remain poor

Clinical Rule: Voriconazole TDM Is Mandatory — Nonlinear Kinetics Mean Standard Dosing Is Unreliable

Voriconazole's saturable hepatic metabolism (primarily CYP2C19) produces nonlinear pharmacokinetics — doubling the dose can more than double the serum level. CYP2C19 poor metabolizers (about 15–20% of Asian populations, 3–5% of White populations) reach levels 4× higher than extensive metabolizers at the same dose. Drug interactions with other CYP2C19 substrates or inhibitors compound this variability further. Trough levels must be checked after steady-state (day 5–7) and after any dose change, drug addition, or clinical change — target trough 1–5.5 mcg/mL. Below 1 mcg/mL: treatment failure risk. Above 5.5 mcg/mL: neurotoxicity, visual disturbances, and hepatotoxicity risk.

For patients with renal impairment and CrCl below 50 mL/min who require IV therapy: the intravenous voriconazole formulation contains SBECD (sulfobutylether-β-cyclodextrin) as a vehicle. SBECD accumulates in renal failure and may cause nephrotoxicity. Switch to oral voriconazole at equivalent doses — bioavailability is ~96% fasted, so oral and IV doses are nearly interchangeable in patients who can take oral medications.

Suggested References

Author / Source Title Publication
Katzung BG, ed. Basic and Clinical Pharmacology, 15th ed. — Chapter 48: Antifungal Agents McGraw-Hill, 2021
Brunton LL, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 57: Antifungal Agents McGraw-Hill, 2023
White TC, Marr KA, Bowden RA Clinical, cellular, and molecular factors that contribute to antifungal drug resistance Clin Microbiol Rev. 1998;11(2):382–402
Groll AH, Piscitelli SC, Walsh TJ Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development Adv Pharmacol. 1998;44:343–500
Saravolatz LD, Johnson LB, Kauffman CA Voriconazole: a new triazole antifungal agent Clin Infect Dis. 2003;36(5):630–637
Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring Antimicrob Agents Chemother. 2012;56(9):4793–4799
Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America Clin Infect Dis. 2016;63(4):e1–e60
Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med. 2007;356(4):348–359
Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease N Engl J Med. 2007;356(4):335–347
Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers Antimicrob Agents Chemother. 2006;50(1):286–293
Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial Lancet. 2016;387(10020):760–769
Sanglard D, Odds FC Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences Lancet Infect Dis. 2002;2(2):73–85
Arendrup MC, Patterson TF Multidrug-resistant Aspergillus versus other pathogens: are we heading toward a pan-azole-resistant world? Med Mycol. 2017;55(1):3–9